GNF SymAtlas + NCI-60 cancer cell lines, human (Su, 2004; Ross, 2000)
Gene | Promoter | Pearson corr. coef. | P-value | Plot |
---|---|---|---|---|
ESR1 | hg38_v1_chr6_+_151807674_151807692 | 0.26 | 9.7e-05 | Click! |
Promoter | Score | Transcript | Gene | Gene Info |
---|---|---|---|---|
chr22_+_22758698 Show fit | 51.15 |
ENST00000390312.2
|
immunoglobulin lambda variable 2-14 |
|
chr22_+_22906342 Show fit | 34.34 |
ENST00000390325.2
|
immunoglobulin lambda constant 3 (Kern-Oz+ marker) |
|
chr22_+_22899481 Show fit | 32.92 |
ENST00000390322.2
|
immunoglobulin lambda joining 2 |
|
chr2_-_89100352 Show fit | 32.20 |
ENST00000479981.1
|
immunoglobulin kappa variable 1-16 |
|
chr2_-_88992903 Show fit | 31.08 |
ENST00000495489.1
|
immunoglobulin kappa variable 1-8 |
|
chr22_+_22904850 Show fit | 30.32 |
ENST00000390324.2
|
immunoglobulin lambda joining 3 |
|
chr22_+_22895368 Show fit | 29.80 |
ENST00000390321.2
|
immunoglobulin lambda constant 1 |
|
chr22_+_22900976 Show fit | 28.90 |
ENST00000390323.2
|
immunoglobulin lambda constant 2 |
|
chr2_-_89213917 Show fit | 28.51 |
ENST00000498435.1
|
immunoglobulin kappa variable 1-27 |
|
chr14_-_105588322 Show fit | 23.05 |
ENST00000497872.4
ENST00000390539.2 |
immunoglobulin heavy constant alpha 2 (A2m marker) |
Log-likelihood per target | Total log-likelihood | Term | Description |
---|---|---|---|
2.7 | 393.4 | GO:0006958 | complement activation, classical pathway(GO:0006958) |
1.0 | 169.4 | GO:0002377 | immunoglobulin production(GO:0002377) |
0.3 | 92.1 | GO:0002250 | adaptive immune response(GO:0002250) |
4.8 | 43.3 | GO:0060267 | positive regulation of respiratory burst(GO:0060267) |
0.4 | 38.6 | GO:0031338 | regulation of vesicle fusion(GO:0031338) |
0.5 | 32.9 | GO:0006953 | acute-phase response(GO:0006953) |
0.4 | 30.2 | GO:0006968 | cellular defense response(GO:0006968) |
9.3 | 28.0 | GO:0000738 | DNA catabolic process, exonucleolytic(GO:0000738) |
1.0 | 23.7 | GO:0006068 | ethanol catabolic process(GO:0006068) |
3.7 | 22.4 | GO:2000110 | negative regulation of macrophage apoptotic process(GO:2000110) |
Log-likelihood per target | Total log-likelihood | Term | Description |
---|---|---|---|
0.2 | 229.3 | GO:0005615 | extracellular space(GO:0005615) |
0.9 | 169.4 | GO:0072562 | blood microparticle(GO:0072562) |
1.7 | 83.6 | GO:0042571 | immunoglobulin complex, circulating(GO:0042571) |
14.4 | 43.2 | GO:0071750 | dimeric IgA immunoglobulin complex(GO:0071750) secretory dimeric IgA immunoglobulin complex(GO:0071752) |
0.4 | 30.6 | GO:0031093 | platelet alpha granule lumen(GO:0031093) |
0.2 | 27.0 | GO:0043202 | lysosomal lumen(GO:0043202) |
0.2 | 19.9 | GO:0032580 | Golgi cisterna membrane(GO:0032580) |
3.1 | 18.8 | GO:0097013 | phagocytic vesicle lumen(GO:0097013) |
0.3 | 18.0 | GO:0015030 | Cajal body(GO:0015030) |
0.7 | 17.1 | GO:0001891 | phagocytic cup(GO:0001891) |
Log-likelihood per target | Total log-likelihood | Term | Description |
---|---|---|---|
2.6 | 608.7 | GO:0003823 | antigen binding(GO:0003823) |
0.2 | 42.3 | GO:0004252 | serine-type endopeptidase activity(GO:0004252) |
0.4 | 37.2 | GO:0004867 | serine-type endopeptidase inhibitor activity(GO:0004867) |
0.2 | 35.3 | GO:0017137 | Rab GTPase binding(GO:0017137) |
9.3 | 28.0 | GO:0008859 | exoribonuclease II activity(GO:0008859) |
5.5 | 21.9 | GO:0032810 | sterol response element binding(GO:0032810) |
0.7 | 21.8 | GO:0001530 | lipopolysaccharide binding(GO:0001530) |
4.7 | 18.8 | GO:0004306 | ethanolamine-phosphate cytidylyltransferase activity(GO:0004306) |
0.7 | 18.0 | GO:0102391 | decanoate--CoA ligase activity(GO:0102391) |
2.0 | 17.8 | GO:0043426 | MRF binding(GO:0043426) |
Log-likelihood per target | Total log-likelihood | Term | Description |
---|---|---|---|
0.5 | 38.7 | PID HNF3A PATHWAY | FOXA1 transcription factor network |
0.2 | 31.5 | PID SMAD2 3NUCLEAR PATHWAY | Regulation of nuclear SMAD2/3 signaling |
0.7 | 29.9 | PID P38 MK2 PATHWAY | p38 signaling mediated by MAPKAP kinases |
0.3 | 17.7 | PID RXR VDR PATHWAY | RXR and RAR heterodimerization with other nuclear receptor |
0.2 | 14.3 | PID RB 1PATHWAY | Regulation of retinoblastoma protein |
0.2 | 13.5 | PID HNF3B PATHWAY | FOXA2 and FOXA3 transcription factor networks |
0.5 | 12.8 | PID ERB GENOMIC PATHWAY | Validated nuclear estrogen receptor beta network |
0.3 | 12.8 | PID INTEGRIN2 PATHWAY | Beta2 integrin cell surface interactions |
0.0 | 9.6 | NABA ECM REGULATORS | Genes encoding enzymes and their regulators involved in the remodeling of the extracellular matrix |
0.2 | 9.5 | PID EPHA FWDPATHWAY | EPHA forward signaling |
Log-likelihood per target | Total log-likelihood | Term | Description |
---|---|---|---|
0.3 | 32.0 | REACTOME INTERFERON ALPHA BETA SIGNALING | Genes involved in Interferon alpha/beta signaling |
0.2 | 30.7 | REACTOME RESPONSE TO ELEVATED PLATELET CYTOSOLIC CA2 | Genes involved in Response to elevated platelet cytosolic Ca2+ |
0.6 | 27.2 | REACTOME AMYLOIDS | Genes involved in Amyloids |
1.3 | 21.0 | REACTOME SYNTHESIS OF PE | Genes involved in Synthesis of PE |
0.2 | 20.0 | REACTOME AMINO ACID AND OLIGOPEPTIDE SLC TRANSPORTERS | Genes involved in Amino acid and oligopeptide SLC transporters |
0.1 | 18.5 | REACTOME PPARA ACTIVATES GENE EXPRESSION | Genes involved in PPARA Activates Gene Expression |
0.4 | 18.4 | REACTOME ANTIGEN ACTIVATES B CELL RECEPTOR LEADING TO GENERATION OF SECOND MESSENGERS | Genes involved in Antigen Activates B Cell Receptor Leading to Generation of Second Messengers |
0.8 | 17.4 | REACTOME TERMINATION OF O GLYCAN BIOSYNTHESIS | Genes involved in Termination of O-glycan biosynthesis |
0.2 | 16.7 | REACTOME NUCLEAR RECEPTOR TRANSCRIPTION PATHWAY | Genes involved in Nuclear Receptor transcription pathway |
0.7 | 15.9 | REACTOME CYTOSOLIC SULFONATION OF SMALL MOLECULES | Genes involved in Cytosolic sulfonation of small molecules |